Trial NCT04921358

View at ClinicalTrials.gov 
Org. Study IDs: BGB-A317-Sitravatinib-301
Secondary IDs: 2022-001779-15 SAFFRON-301

Last trial update was posted on 2024-02-28

MeSH Interventions

Docetaxel Tislelizumab

MeSH Conditions

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Other Conditions

Non-Small Cell Lung Cancer (NSCLC)

Stopping Reasons

Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID